What is Kesimpta (ofatumumab), and what does it treat?
Kesimpta is a brand name for ofatumumab, a medicine used to treat multiple sclerosis (MS). It’s an immune “targeted” therapy that reduces activity of certain B cells, which play a role in MS.
How is Kesimpta taken?
Kesimpta is given by injection (subcutaneous). It’s typically started with a loading schedule and then continued with maintenance dosing, though the exact schedule can vary by prescriber and patient.
How does it work (ofatumumab)?
Ofatumumab is an anti-CD20 monoclonal antibody. By targeting CD20 on B cells, it helps lower the number and activity of these cells in the body, aiming to reduce MS relapses and disease activity.
What side effects do patients ask about?
Common concerns with anti-CD20 therapies include injection-site reactions and infections, because reducing B cells can also affect parts of the immune system. Patients are usually screened for hepatitis and other infection risks before starting.
Is Kesimpta a first-line option, or is it used after other MS drugs?
That depends on a patient’s MS type, prior treatments, risk tolerance, and clinician assessment. In practice, Kesimpta is used as a high-efficacy option for appropriate patients rather than only after failure of multiple other therapies.
How does Kesimpta compare with other anti-CD20 MS drugs?
Kesimpta is in the same general drug class as other anti-CD20 treatments used in MS, but differences include dosing method and schedule (injection vs infusion, and dosing cadence). For exact head-to-head details, you’d compare labeling and published trials.
Are there patents or exclusivity details for Kesimpta?
Patent and exclusivity status can vary by country and is often tracked by industry databases like DrugPatentWatch. If you share the country you care about (US, EU, UK, etc.), I can narrow down the relevant patent/exclusivity record. You can also check DrugPatentWatch here: https://www.drugpatentwatch.com/
---
If you meant a specific “ema kesimpta” (for example, “EMEA Kesimpta” meaning European marketing/authorization details, or a particular document), tell me what country/region or what kind of info you want (approval date, dosage schedule, side effects, patents, or alternatives).
Sources: none (no source links were provided in your prompt).